Bayer: Science For A Better Life

United States of America

Oncology Information for Grant Submissions

CFG closing date: 12/1/22
CFG – TKI – GIST

Call For Grant
Budget - $150,000

Intended Audience: Oncologist, Nurse, Nurse Practitioner, Pharmacist

Bayer TA Rationale for Educational Support:

  • Role of TKIs in the treatment paradigm and AE management in GIST, including:
    • considerations for treatment sequencing in Imatinib-refractory GIST
    • Stratification of treatment choices based on primary & secondary mutational subtypes

Preferred Format:

  • Enduring
  • Downloadable slides
  • Podcast
  • Virtual

Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).

The proposal should include:

  • Needs assessment
  • Educational design and rationale for selection (where applicable)
  • Learning Objectives & Draft Agenda
  • Proposed Faculty
  • Participant recruitment plan (where applicable)
  • Outcomes strategy/plan
  • Detailed budget (please use the template available on the website)

Provider Justification:

Copy of most recent accreditation letter and status

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

  • Provide timely updates on changes in project timeline and event launch date
  • Reconcile grant funding within 60 days of completion of the educational program
  • Permit a Bayer Medical Affairs representative to audit live programs
  • Share activity data and outcomes metrics within 30 days of their availability

References

  • National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Gastrointestinal Stromal Tumors (GIST). Version 2.2022 – September 1, 2022 (link)
  • Kelly CM et al. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021 Jan 5;14(1):2 (link)
  • Al-Share B, et al. Gastrointestinal stromal tumor: a review of current and emerging therapies. Cancer Metastasis Rev. 2021 Jun;40(2):625-641 (link)
  • Call, JW et al. Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry. Clin Sarcoma Res. 2019 Apr 2;9:4. (link)
  • Nannini M, et al. Complete radiological response to first-line regorafenib in a patient with abdominal relapse of BRAF V600E mutated GIST. Therap Adv Gastroenterol. 2020 Jun 30 (link)
  • Demetri G et al. Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal stromal tumors (GIST). J Clin Onc 34, no. 4_suppl (February 01, 2016) 156-156 (link)
  • Demetri G et al. Long-term safety of regorafenib (REG) in advanced gastrointestinal stromal tumors (GIST): updated safety data of the phase 3 GRID trial. Annals of Oncology Volume 27, 2016 Supplement 6, 2447 (link)
  • Ben-Ami E et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016 Sep;27(9):1794-9 (link)
  • Poole CD, et al. Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo. Gastric Cancer. 2015 Jul;18(3):627-34 (link)
  • Demetri G, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID): an international, multicenter, randomized, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):295-302 (link)
  • George S, Wang Q, Heinrich M, et al. Efficacy and Safety of Regorafenib in Patients with metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial. JCO. 2012 Jul 30 (19): 2401-2407 (link)
  • Rizzo A, et al. Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020 Jul 7;12:1758835920936932 (link)
  • Grothey, A et al. Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR); Annals of Oncology 30 (5), October 2019 (link)